FOXP3 as an X-linked tumor suppressor

Area of Science:

• Genetics
• Oncology
• Immunology

Background:

• The FOXP3 gene is crucial for immune regulation and was initially identified due to its role in lethal autoimmune diseases.
• Mutations in the FOXP3 gene (or its mouse homolog, FoxP3) are associated with spontaneous mammary tumors in mice and prostate intraepithelial neoplasia.
• Somatic mutations, deletions, and epigenetic silencing of FOXP3 are frequently observed in human breast and prostate cancers.

Purpose of the Study:

• To investigate the role of the FOXP3 gene in the development of mammary and prostate cancers.
• To explore the mechanism of FOXP3 inactivation in cancer, particularly its X-linked nature.
• To identify potential therapeutic strategies based on FOXP3's function in cancer.

Main Methods:

• Analysis of FOXP3 gene status (mutations, deletions, epigenetic inactivation) in human breast and prostate cancer samples.
• Comparison of FOXP3 inactivation patterns in cancer with those of autosomal tumor suppressor genes.
• Investigation of X-chromosome inactivation patterns in cancer cells with FOXP3 mutations.

Main Results:

• FOXP3 inactivation is widespread in human breast and prostate cancers.
• Unlike autosomal tumor suppressors, FOXP3 inactivation in cancer is typically heterozygous.
• Evidence of selective inactivation of the wildtype FOXP3 allele in cancer cells, suggesting skewed X-inactivation.

Conclusions:

• The FOXP3 gene functions as a tumor suppressor in mammary and prostate tissues.
• Skewed X-inactivation leading to selective loss of functional FOXP3 is a key mechanism in these cancers.
• Reactivation of FOXP3 presents a novel therapeutic avenue for treating breast and prostate cancers.